|
US5525465A
(en)
*
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
|
US5087617A
(en)
*
|
1989-02-15 |
1992-02-11 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treatment of cancer using oligonucleotides
|
|
US5670617A
(en)
*
|
1989-12-21 |
1997-09-23 |
Biogen Inc |
Nucleic acid conjugates of tat-derived transport polypeptides
|
|
GB9209032D0
(en)
|
1992-04-25 |
1992-06-10 |
Ciba Geigy Ag |
New peptide derivatives
|
|
ES2123062T3
(es)
|
1992-08-21 |
1999-01-01 |
Biogen Inc |
Polipeptidos de transporte derivados de la proteina tat.
|
|
DE69429087T2
(de)
*
|
1993-01-07 |
2002-07-11 |
Thomas Jefferson University, Philadelphia |
Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc
|
|
US5849727A
(en)
*
|
1996-06-28 |
1998-12-15 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for altering the biodistribution of biological agents
|
|
CN1263473A
(zh)
*
|
1997-05-21 |
2000-08-16 |
利兰·斯坦福青年大学托管委员会 |
增加跨生物膜转运的组合物和方法
|
|
AU5583799A
(en)
|
1998-08-25 |
2000-03-14 |
Human Genome Sciences, Inc. |
49 human secreted proteins
|
|
KR20010102992A
(ko)
*
|
1999-01-29 |
2001-11-17 |
추후보정 |
표적 ｒｎａ를 검출하는 비-침입적 방법
|
|
CA2365984A1
(en)
*
|
1999-04-08 |
2000-10-19 |
Oasis Biosciences, Inc. |
Antisense oligonucleotides comprising universal and/or degenerate bases
|
|
DE60039601D1
(de)
|
1999-05-24 |
2008-09-04 |
Avi Biopharma Inc |
Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
|
|
US6875747B1
(en)
|
1999-05-24 |
2005-04-05 |
Avi Bio Pharma, Inc. |
Antisense to c-myc for treatment of polycystic kidney disease
|
|
US6303573B1
(en)
*
|
1999-06-07 |
2001-10-16 |
The Burnham Institute |
Heart homing peptides and methods of using same
|
|
US7229961B2
(en)
|
1999-08-24 |
2007-06-12 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into ocular tissues
|
|
US6593292B1
(en)
|
1999-08-24 |
2003-07-15 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
|
US6669951B2
(en)
|
1999-08-24 |
2003-12-30 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
|
US20030104622A1
(en)
|
1999-09-01 |
2003-06-05 |
Robbins Paul D. |
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
|
|
US20020009491A1
(en)
|
2000-02-14 |
2002-01-24 |
Rothbard Jonathan B. |
Compositions and methods for enhancing drug delivery across biological membranes and tissues
|
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
|
US20040170955A1
(en)
*
|
2000-09-08 |
2004-09-02 |
Wadih Arap |
Human and mouse targeting peptides identified by phage display
|
|
EP1191097A1
(en)
*
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
WO2002038764A2
(en)
|
2000-11-10 |
2002-05-16 |
The Regents Of The University Of California |
Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
|
|
WO2002063280A1
(en)
*
|
2001-02-06 |
2002-08-15 |
Auburn University |
Ligand sensor devices and uses thereof
|
|
AU2002250034A1
(en)
|
2001-02-08 |
2002-08-19 |
Sequitur, Inc. |
Methods of light activated release 0f ligands from endosomes
|
|
DE60233137D1
(de)
*
|
2001-02-16 |
2009-09-10 |
Univ R |
Transporter mit beabstandeten arginin-teilchen
|
|
US7456146B2
(en)
|
2001-05-09 |
2008-11-25 |
Ghc Research Development Corporation |
Lytic peptide prodrugs
|
|
NZ530101A
(en)
*
|
2001-05-17 |
2007-01-26 |
Avi Biopharma Inc |
Methods for treating cancer by administering an oligomer antisense to c-myc together with a cancer chemotherapeutic agent
|
|
JP3735292B2
(ja)
|
2001-07-26 |
2006-01-18 |
三菱重工業株式会社 |
ダイエット効果のある健康食品および製剤
|
|
US6645974B2
(en)
*
|
2001-07-31 |
2003-11-11 |
Merck & Co., Inc. |
Androgen receptor modulators and methods for use thereof
|
|
US20090075377A1
(en)
|
2001-08-03 |
2009-03-19 |
Arbor Vita Corporation |
Molecular interactions in cells
|
|
WO2003049772A2
(en)
*
|
2001-12-11 |
2003-06-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Guanidinium transport reagents and conjugates
|
|
WO2004084805A2
(en)
|
2003-03-19 |
2004-10-07 |
The J. David Gladstone Institutes |
Acetylated tat polypeptides and methods of use thereof
|
|
US7468418B2
(en)
*
|
2003-04-29 |
2008-12-23 |
Avi Biopharma., Inc. |
Compositions for enhancing transport of molecules into cells
|
|
EP2784084B2
(en)
|
2003-07-08 |
2023-10-04 |
Novartis Pharma AG |
Antagonist antibodies to IL-17A/F heterologous polypeptides
|
|
US20050203041A1
(en)
|
2003-09-23 |
2005-09-15 |
Mourich Dan V. |
Antisense compound and method for selectively killing activated T cells
|
|
US20050222068A1
(en)
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
|
US7786151B2
(en)
*
|
2004-01-09 |
2010-08-31 |
Kinopharma, Inc. |
Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction
|
|
CA2553104A1
(en)
*
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
WO2005077333A2
(en)
*
|
2004-02-10 |
2005-08-25 |
University Of Florida Research Foundation, Inc. |
Gel-based delivery of recombinant adeno-associated virus vectors
|
|
US7402574B2
(en)
|
2004-03-12 |
2008-07-22 |
Avi Biopharma, Inc. |
Antisense composition and method for treating cancer
|
|
US20050288246A1
(en)
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
US20060014712A1
(en)
*
|
2004-05-30 |
2006-01-19 |
Cemines, Inc. |
Controlled delivery of therapeutic compounds
|
|
EP2933332A1
(en)
|
2004-06-28 |
2015-10-21 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
EP1789553B1
(en)
|
2004-06-30 |
2014-03-26 |
Alnylam Pharmaceuticals Inc. |
Oligonucleotides comprising a non-phosphate backbone linkage
|
|
US7947645B2
(en)
|
2004-09-02 |
2011-05-24 |
Cognosci, Inc. |
APO E analogs and methods for their use
|
|
WO2006031996A2
(en)
|
2004-09-14 |
2006-03-23 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Targeting viruses using a modified sindbis glycoprotein
|
|
US8129352B2
(en)
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
US8357664B2
(en)
|
2004-10-26 |
2013-01-22 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
|
US7524829B2
(en)
|
2004-11-01 |
2009-04-28 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
EP1855694B1
(en)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense composition for treating muscle atrophy
|
|
GT200600065A
(es)
|
2005-02-14 |
2006-10-02 |
|
Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
|
|
WO2006114478A1
(en)
|
2005-04-26 |
2006-11-02 |
Karyon-Ctt Ltd |
Diagnostic and therapeutic agents
|
|
WO2007009094A2
(en)
|
2005-07-13 |
2007-01-18 |
Avi Biopharma, Inc. |
Antisense antibacterial method and compound
|
|
US7790694B2
(en)
*
|
2005-07-13 |
2010-09-07 |
Avi Biopharma Inc. |
Antisense antibacterial method and compound
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
US8524676B2
(en)
|
2005-09-08 |
2013-09-03 |
Sarepta Therapeutics, Inc. |
Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
|
|
WO2007030576A2
(en)
|
2005-09-08 |
2007-03-15 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
|
EP1941275B1
(en)
|
2005-09-29 |
2013-07-24 |
Medimmune, Inc. |
Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
|
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
|
US20070111962A1
(en)
|
2005-11-08 |
2007-05-17 |
Mourich Dan V |
Immunosuppression compound and treatment method
|
|
US7582615B2
(en)
|
2006-03-07 |
2009-09-01 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating arenavirus infection
|
|
US8785407B2
(en)
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
PL2735568T3
(pl)
|
2006-05-10 |
2018-02-28 |
Sarepta Therapeutics, Inc. |
Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
|
|
AU2006345724B2
(en)
|
2006-06-30 |
2013-11-21 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
|
SI2049664T1
(sl)
|
2006-08-11 |
2012-04-30 |
Prosensa Technologies Bv |
Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev
|
|
US20080199961A1
(en)
|
2006-08-25 |
2008-08-21 |
Avi Biopharma, Inc. |
ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
|
|
US20080267978A1
(en)
|
2006-08-28 |
2008-10-30 |
Mary Zutter |
Anti-angiogenic targets for cancer therapy
|
|
EP2560001B1
(en)
|
2006-09-21 |
2016-04-13 |
University of Rochester |
Compositions and methods related to protein displacement therapy for myotonic distrophy
|
|
FR2908999B1
(fr)
|
2006-11-29 |
2012-04-27 |
Biomerieux Sa |
Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
|
|
EP1938802A1
(en)
|
2006-12-22 |
2008-07-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Interfering RNAs targeting pro-inflammatory cytokines
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
WO2009005793A2
(en)
|
2007-06-29 |
2009-01-08 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
|
US20110300154A1
(en)
|
2007-08-21 |
2011-12-08 |
Children's Medical Center Corporation |
Treatment of airway hyperreactivity
|
|
EP2235034B1
(en)
|
2007-12-28 |
2016-11-23 |
Sarepta Therapeutics, Inc. |
Immunomodulatory agents and methods of use
|
|
WO2009144481A2
(en)
|
2008-05-30 |
2009-12-03 |
Isis Innovation Limited |
Conjugates for delivery of biologically active compounds
|
|
BR122020021379B1
(pt)
|
2008-10-24 |
2021-05-11 |
Sarepta Therapeutics, Inc. |
oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
|
|
EP2376633A1
(en)
|
2008-12-17 |
2011-10-19 |
AVI BioPharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
CA3090304A1
(en)
|
2010-05-13 |
2011-11-17 |
Sarepta Therapeutics, Inc. |
Antisense modulation of interleukins 17 and 23 signaling
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|